MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Levodopa(L-dopa)"

  • 2018 International Congress

    Clinical experiences in Whole systems Ayurveda Management of Parkinson’s Disease

    P. Shankar, P. R, P. Devkumar, A. Godbole, U. Muthane (Bangalore, India)

    Objective: PD Assessment of Ayurveda management using UPDRS -Motor, Hoehn & Yahr staging, Activity of Daily Living % (ADL). Background: Ayurveda holistic management comprises an…
  • 2018 International Congress

    Sensory signs and neuropathic pain in advanced Parkinson’s disease under levodopa treatment

    A.E. Elia, G. Devigili, M. Damasco, L.M. Romito, P. Soliveri, S. Rinaldo, M. Falsitta, R. Eleopra (Milan, Italy)

    Objective: To evaluate whether patients affected by Parkinson’s disease (PD) under levodopa/carbidopa intestinal gel (LCIG) therapy have alterations in sensory symptoms and signs and/or painful…
  • 2018 International Congress

    Does the effect of continuous levodopa infusion treatment for Parkinson’s disease regress as the day progresses?

    I. Thomas, M. Memedi, D. Nyholm, J. Westin (Borlange, Sweden)

    Objective: The goal of this project is to examine if there is evidence to suggest that there is a difference in response to levodopa during…
  • 2018 International Congress

    Epidemiological and clinical profile of Parkinson’s disease in Douala

    J. Doumbe, H. Bohongwe, Y. Mapoure, C. Kuate (Douala, Cameroon)

    Objective: The aim of our study was to determine the hospital prevalence and describe the epidemiological and clinical profile of Parkinson’s disease in Douala Background:…
  • 2018 International Congress

    Impact of Age on Levodopa dosage regimes in Idiopathic Parkinson’s Disease

    L. Scourfield, S. Sultana, C. Thomas, B. Mohamed (Cardiff, United Kingdom)

    Objective: To assess the influence of patient age on prescribed dosage and subsequent dose escalation regimes of levodopa therapy in a cohort of people with…
  • 2018 International Congress

    A case of levodopa responsive rapid onset dystonia-parkinsonism

    Y. Fernandez, S. Frucht (New York, NY, USA)

    Objective: We describe and demonstrate by video a young man with rapid onset dystonia parkinsonism who has a robust response to levodopa. Background: Rapid onset…
  • 2018 International Congress

    Effect of medication on lexical tone production in Cantonese patients with Parkinson’s Disease

    A. Chan, S. Chen, J. Shao, C.C. Zhang, I. Lam, S. Pang, V. Ngan, J. Tam, W.C. Yang, J. Ngan, S. Pinto (Hong Kong)

    Objective: To examine how dysarthria resulting from Parkinson’s Disease (PD) affects lexical tone production in Cantonese-speaking patients and to evaluate the effects of medication Background:…
  • 2018 International Congress

    Efficacy and safety of safinamide as a levodopa adjunct in patients with parkinson disease and motor fluctuations: A systematic review of randomized controlled trials

    S. Hussain, A. Najmi (New Delhi, India)

    Objective: To assess the efficacy and safety of safinamide as an add-on therapy to levodopa in Parkinson patients. Background: Long-term use of levodopa is associated…
  • 2018 International Congress

    On Converting Patients From Oral Dopamine Agonists to the Carbidopa/Levodopa Enteral Suspension Method – Real World Conversion Ratios

    S. Nakano, L. Bahroo, F. Pagan, F. Amjad, S. Lo, I. Gambhir (Washington, D.C., DC, USA)

    Objective: To review guidelines for initiating Carbidopa/Levodopa Enteral Suspension method of delivery in the treatment of Parkinson’s Disease (PD) and to compare guidelines with real…
  • 2018 International Congress

    Impact of Dyskinesia in Parkinson’s Disease (PD) on Activities of Daily Living (ADLs) and Daily Tasks: Results from Pooled Phase 3 ADS-5102 Clinical Trials

    R. Pahwa, S. Isaacson, J. Jimenez-Shahed, I. Malaty, A. Deik, R. Gandhy, R. Johnson, R. Patni (Kansas City, KS, USA)

    Objective: To assess the impact of dyskinesias in PD on ADLs and the effects of ADS-5102 (amantadine) extended release capsules on these impairments. Background: ADS-5102…
  • « Previous Page
  • 1
  • …
  • 40
  • 41
  • 42
  • 43
  • 44
  • …
  • 57
  • Next Page »

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
    • #25062 (not found)
    • Welcome to the MDS Abstracts Site
    • Effect of marijuana on Essential Tremor: A case report
    • Advanced Search
    • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
    • Covid vaccine induced parkinsonism and cognitive dysfunction
    • Help & Support
    • About Us
    • Cookies & Privacy
    • Wiley Job Network
    • Terms & Conditions
    • Advertisers & Agents
    Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
    Wiley